Cwm LLC Has $921,000 Position in IQVIA Holdings Inc. (NYSE:IQV)

Cwm LLC raised its position in IQVIA Holdings Inc. (NYSE:IQV) by 5.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,980 shares of the medical research company’s stock after buying an additional 207 shares during the quarter. Cwm LLC’s holdings in IQVIA were worth $921,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. AMF Tjanstepension AB acquired a new stake in IQVIA in the 3rd quarter worth about $148,096,000. Eagle Asset Management Inc. acquired a new stake in IQVIA during the third quarter worth approximately $102,982,000. iA Global Asset Management Inc. increased its stake in IQVIA by 1,225.3% during the 3rd quarter. iA Global Asset Management Inc. now owns 320,271 shares of the medical research company’s stock worth $63,013,000 after acquiring an additional 296,105 shares during the period. Connor Clark & Lunn Investment Management Ltd. raised its holdings in IQVIA by 2,765.6% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 271,316 shares of the medical research company’s stock valued at $53,381,000 after acquiring an additional 261,848 shares in the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. raised its holdings in IQVIA by 33.4% in the 4th quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,039,436 shares of the medical research company’s stock valued at $240,505,000 after acquiring an additional 260,271 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analyst Upgrades and Downgrades

IQV has been the topic of several recent analyst reports. BTIG Research started coverage on shares of IQVIA in a report on Tuesday, February 13th. They issued a “buy” rating and a $285.00 target price on the stock. StockNews.com upgraded IQVIA from a “hold” rating to a “buy” rating in a research note on Friday, February 16th. UBS Group lifted their price target on IQVIA from $240.00 to $300.00 and gave the company a “buy” rating in a research note on Thursday, February 15th. Barclays upped their price objective on IQVIA from $260.00 to $265.00 and gave the stock an “overweight” rating in a research report on Thursday, February 15th. Finally, Guggenheim cut IQVIA from a “buy” rating to a “neutral” rating in a research report on Thursday, February 15th. Three analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $256.80.

IQVIA Stock Up 0.4 %

Shares of NYSE IQV opened at $234.88 on Monday. IQVIA Holdings Inc. has a 1 year low of $167.42 and a 1 year high of $261.73. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.86 and a quick ratio of 0.86. The firm has a market cap of $42.63 billion, a PE ratio of 32.22, a price-to-earnings-growth ratio of 2.27 and a beta of 1.50. The company has a 50 day simple moving average of $245.28 and a 200 day simple moving average of $223.30.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Wednesday, February 14th. The medical research company reported $2.84 earnings per share for the quarter, topping the consensus estimate of $2.82 by $0.02. The company had revenue of $3.87 billion for the quarter, compared to analysts’ expectations of $3.80 billion. IQVIA had a net margin of 9.06% and a return on equity of 29.32%. IQVIA’s revenue for the quarter was up 3.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.54 earnings per share. On average, research analysts forecast that IQVIA Holdings Inc. will post 10.12 EPS for the current year.

Insider Buying and Selling

In other IQVIA news, insider Kevin C. Knightly sold 8,607 shares of the stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $250.17, for a total transaction of $2,153,213.19. Following the completion of the sale, the insider now owns 5,251 shares of the company’s stock, valued at approximately $1,313,642.67. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other IQVIA news, insider Kevin C. Knightly sold 8,607 shares of the company’s stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $250.17, for a total transaction of $2,153,213.19. Following the sale, the insider now owns 5,251 shares of the company’s stock, valued at $1,313,642.67. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Ari Bousbib sold 31,678 shares of IQVIA stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $250.53, for a total value of $7,936,289.34. Following the completion of the transaction, the insider now directly owns 796,752 shares of the company’s stock, valued at $199,610,278.56. The disclosure for this sale can be found here. Insiders have sold a total of 41,285 shares of company stock valued at $10,331,003 over the last ninety days. 1.60% of the stock is owned by company insiders.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.